Review
Medicine, General & Internal
Malgorzata Satora, Arkadiusz Grunwald, Bartlomiej Zaremba, Karolina Frankowska, Klaudia Zak, Rafal Tarkowski, Krzysztof Kulak
Summary: There are diverse treatment options for vulvovaginal candidiasis (VVC), including oteseconazole and ibrexafungerp. However, there is inconsistency in the latest recommendations and novel treatment options for VVC.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Mycology
Siyue Kan, Nana Song, Qiuyu Pang, Huan Mei, Hailin Zheng, Dongmei Li, Fan Cui, Guixia Lv, Ruifang An, Ping Li, Zhengai Xiong, Shangrong Fan, Mengzhen Zhang, Yanhong Chen, Qiao Qiao, Xudong Liang, Manhua Cui, Dongyan Li, Qinping Liao, Xiaofang Li, Weida Liu
Summary: Vulvovaginal candidiasis is a global public health issue, and the optimal treatment for recurrent VVC has not been established. In vitro antifungal susceptibility profiling of VVC isolates from different regions of China can provide significant improvements for the control and treatment of this disease.
Article
Microbiology
Jian Miao, Jessica Regan, Chun Cai, Glen E. Palmer, David L. Williams, Michael D. Kruppa, Brian M. Peters
Summary: This study characterizes the glycogen metabolism pathways in Candida albicans and shows that glycogen metabolism is important for the long-term survival and virulence of the fungus.
Article
Immunology
Paul Nyirjesy, Jane R. Schwebke, David A. Angulo, Itzel A. Harriott, Nkechi E. Azie, Jack D. Sobel
Summary: The study demonstrates that single-day ibrexafungerp treatment for acute vulvovaginal candidiasis is well tolerated and provides similar efficacy to single-dose fluconazole 150 mg.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Microbiology
Xiaoqian Wang, Lihong Chen, Hongjie Ruan, Zhengai Xiong, Wenying Wang, Jin Qiu, Weihua Song, Chunlian Zhang, Fengxia Xue, Tianhua Qin, Bei Zhang, Ruifang An, Xiping Luo, Wei Wang, Songling Zhang, Yunlang Cai, Jiali Kang, Henan Deng, Shangrong Fan, Manhua Cui, Shijin Wang, Xiaowan Luo, Zhiying Su, Jing Shu, Quanren Wang, Fang Wang, Jianling Bai, Qinping Liao, Damian J. Krysan
Summary: Fluconazole remains the dominant treatment option for severe vulvovaginal candidiasis (VVC), but this study found that Oteseconazole demonstrated significant and clinically meaningful superiority in treating severe VVC with good tolerability.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Ari Soares de Oliveira Neto, Israel Lucas Antunes Souza, Maria Eliza Samuel Amorim, Thalita de Freitas Souza, Vinicius Novaes Rocha, Rene Oliveira do Couto, Rodrigo Luiz Fabri, Marcelo Gonzaga de Freitas Araujo
Summary: This study demonstrated the antifungal activity of atorvastatin and its potential as a therapeutic agent for treating Candida albicans infections. Atorvastatin-containing oral and vaginal emulgels showed effective treatment outcomes for oral and vulvovaginal candidiasis in animal models, suggesting its promising application for drug repositioning in the treatment of opportunistic mycoses.
Article
Immunology
Zhixia Chen, Jing Jin, Huichao Chen, Ying Chen, Shuyi Feng
Summary: The incidence of vaginal infection caused by Candida species has increased over the past two decades. Candida albicans is the main cause of vulvovaginal candidiasis (VVC), but non-albicans Candida (NAC) species are now frequently identified in VVC patients. The fungal influence on bacterial communities and potential microbial interaction contributing to VVC pathology in NAC species-associated VVC remain unclear. Taxonomic analysis revealed that the vaginal microbiome in C. glabrata-associated VVC women is different from that of other Candida species-associated VVC women, suggesting a different pathogenesis.
MICROBIAL PATHOGENESIS
(2023)
Article
Immunology
Jingyun Zhang, Jingwen Peng, Dongmei Li, Huan Mei, Yu Yu, Xiaofang Li, Xiaodong She, Weida Liu
Summary: Vulvovaginal candidiasis is characterized by inflammatory responses in the vagina caused by Candida albicans and non-albicans Candida species. This study found that different Candida strains and species induce different host immune responses and epithelial damage. The EGFR-MAPK signaling pathway plays an important role in the pathogenesis of vulvovaginal candidiasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Instruments & Instrumentation
Anugerah Yaumil Ramadhani Aziz, Ulfah Mahfufah, Nor Atikah Syahirah, Habibie, Rangga Meidianto Asri, Risfah Yulianty, Ria Fajarwati Kastian, Yessie Widya Sari, Lutfi Chabib, Hasyrul Hamzah, Andi Dian Permana
Summary: This study developed a combination approach of nanocrystals and dissolving microneedles for effective local vaginal delivery of fluconazole (FLZ). The formulation exhibited a small particle size and superior release performance, and showed better anti-candidiasis activity compared to other preparations in a vaginal model.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Paulina Czechowicz, Damian Neubauer, Joanna Nowicka, Wojciech Kamysz, Grazyna Gosciniak
Summary: The study found that cyclic analogs of ultrashort cationic lipopeptides exhibited enhanced antifungal activity against vaginal candidiasis compared to their linear analogs. Additionally, a synergistic effect was observed when linear lipopeptides were combined with fluconazole, leading to decreased minimum inhibitory concentrations. Further in vivo studies are needed to confirm the benefits of combination therapy using USCLs and fluconazole at low non-toxic concentrations.
Article
Immunology
Jane R. Schwebke, Ryan Sobel, Janet K. Gersten, Steven A. Sussman, Samuel N. Lederman, Mark A. Jacobs, B. Todd Chappell, David L. Weinstein, Alfred H. Moffett, Nkechi E. Azie, David A. Angulo, Itzel A. Harriott, Katyna Borroto-Esoda, Mahmoud A. Ghannoum, Paul Nyirjesy, Jack D. Sobel
Summary: Ibrexafungerp showed superior efficacy to placebo in treating acute vulvovaginal candidiasis, with mild adverse events and consistent effectiveness across different subpopulations.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Microbiology
Emily McKloud, Christopher Delaney, Leighann Sherry, Ryan Kean, Shanice Williams, Rebecca Metcalfe, Rachael Thomas, Riina Richardson, Konstantinos Gerasimidis, Christopher J. Nile, Craig Williams, Gordon Ramage
Summary: This study identified changes in vaginal microbiome in RVVC, showing a reduction in Lactobacillus crispatus and an increase in Lactobacillus iners. The presence of Candida albicans biofilm formation and interactions with Lactobacillus species were also highlighted, suggesting potential mechanisms for RVVC and the importance of understanding these interactions for developing effective therapies.
Article
Pharmacology & Pharmacy
Fiama Martins, Daniella L. Morgado, Bruno Sarmento, Emerson R. de Camargo, Jose das Neves
Summary: Vulvovaginal candidiasis is a concerning issue in women's healthcare, and better treatment options are needed. The chitosan sponge formulations developed in this study show promise as alternative antifungal products, with improved safety and effectiveness.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Infectious Diseases
Gabriela Correa Carvalho, Rafaela Aparecida Prata de Oliveira, Victor Hugo Sousa Araujo, Rafael Miguel Sabio, Lidia Raquel de Carvalho, Tais Maria Bauab, Ione Correa, Marlus Chorilli
Summary: Vulvovaginal candidiasis (CVV) is the second leading cause of vaginitis in the world, with an estimated prevalence of 18% in Brazil. Studies show higher prevalence in the South and Southeast regions compared to the North and Northeast regions, with no data available for the Midwest region. Further epidemiological studies are recommended to fully understand the disease profile in Brazil.
Article
Microbiology
Arianna Sala, Andrea Ardizzoni, Luca Spaggiari, Nikhil Vaidya, Jane van der Schaaf, Cosmeri Rizzato, Claudio Cermelli, Selene Mogavero, Thomas Krueger, Maximilian Himmel, Olaf Kniemeyer, Axel A. Brakhage, Benjamin L. King, Antonella Lupetti, Manola Comar, Francesco de Seta, Arianna Tavanti, Elisabetta Blasi, Robert T. Wheeler, Eva Pericolini
Summary: Despite a high incidence of VVC, our understanding of this female-specific disease is still limited, and it has become a public health issue due to its negative impact on women's quality of life. It is not yet possible to determine if a specific Candida albicans strain is more likely to cause VVC based on genotype or laboratory phenotype. VVC affects nearly 3/4 of women and significantly reduces their quality of life.